Explor Target Antitumor Ther ETAT Exploration of Targeted Anti-tumor Therapy 2692-3114 Open Exploration Publishing 10.37349/etat.2025.1002329 1002329 Review Dysbiosis and colorectal cancer: conducive factors, biological and molecular role, and therapeutic prospectives Singh Gurkaranjot Conceptualization Methodology Writing—original draft 1 Chaudhry Zuhair Conceptualization Methodology Writing—original draft 1 Boyadzhyan Anik Conceptualization Methodology Writing—original draft 1 Sasaninia Kayvan Conceptualization Methodology Writing—original draft 1 https://orcid.org/0000-0001-6286-2341 Rai Vikrant Writing—review & editing 1 2 * Maurel Joan Academic Editor University of Barcelona, Spain 1College of Osteopathic Medicine of the Pacific, Western University of Health Sciences, Pomona, CA 91766, USA 2Department of Translational Research, Western University of Health Sciences, Pomona, CA 91766, USA *Correspondence: Vikrant Rai, Department of Translational Research, Western University of Health Sciences, 309 E. Second Street, Pomona, CA 91766, USA. vrai@westernu.edu 2025 27 06 2025 6 1002329 03 02 2025 19 05 2025 © The Author(s) 2025. This is an Open Access article licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Colorectal cancer (CRC) is the third leading cause of cancer-related death in the United States. Emerging evidence highlights the significant role of gut microbiota dysbiosis, characterized by a reduction in beneficial bacteria and an increase in pro-inflammatory and pro-carcinogenic bacteria, in CRC pathogenesis. Both genetic and environmental factors, including diet, antibiotic use, physical activity, aging, and obesity, contribute to this microbial imbalance. Dysbiosis promotes chronic inflammation and immune dysregulation, which facilitates tumor initiation and progression. This review examines the intricate interactions between gut microbiota, immune modulation, and CRC development. It explores current and emerging therapeutic strategies that target the microbiome to enhance treatment efficacy, discusses interventions aimed at restoring healthy microbiota in CRC patients, and outlines future directions for microbiome-based therapies to improve clinical outcomes.

 Colorectal cancer intestinal microbiome inflammation dysbiosis immunomodulation therapeutics Introduction

Colorectal cancer (CRC) imposes a great deal on global health; it is the third most frequent cancer diagnosis and the third leading cause of cancer-related deaths in both genders in the US. The second most common killer among all cancer-related deaths is CRC, and in men under 50 years of age, it is the leading cause [1]. Men are approximately 1.5 times more likely than women to develop CRC, regardless of age or ethnicity [2]. African Americans tend to have an earlier onset, higher mortality, and higher incidence [3]. The survival rate for patients with localized cancer is 90% at 5 years, and for patients across all stages of CRC combined is 63% at 5 years [4]. However, metastatic CRC still proves to be lethal, as the 5-year survival rate is around 14% [5]. CRC in the colon or rectum results from the growth of the glandular epithelial cells inside the colon or the rectum [6].

Individuals with an increased risk of CRC include those who have had cancer, a history of colon polyps, inflammatory bowel disease (IBD), diabetes mellitus, or cholecystectomy. Lifestyle factors, including overweight and obesity, physical inactivity, cigarette smoking, alcohol consumption, a diet low in fiber, fruits, vegetables, calcium, and dietary products, and a diet high in red and processed meat, increase CRC risk. In addition, gut microbiome, age, gender, race, and socioeconomic status are known to influence the risk of CRC [7]. Typical symptoms of CRC include rectal bleeding, iron deficiency anemia, weight loss, fatigue, and/or abdominal/rectal pain [4, 8]. CRC develops either sporadically, which is the vast majority of cases, or heritably, which makes up 10% of cases [9]. Because of its genetic pathogenesis, the prevention of CRC is difficult, and that is why screening plays an important role in fighting cancer. Stool-based tests, computed tomography colonography, and sigmoidoscopy are the main methods to diagnose CRC. Stool-based tests include the guaiac fecal occult blood test (gFOBT), detecting blood in stool via pseudoperoxidase activity of heme, and the fecal immunochemical test (FIT) using antibodies to detect human globin. Sigmoidoscopy provides direct visualization of the colorectum and the opportunity to biopsy and/or remove polyps [10]. Sigmoidoscopy has led to a notable decrease of 20% in the incidence of CRC [11]. Despite these screening modalities, the prevalence of CRC is increasing. Thus, there is a need to understand the underlying molecular mechanisms, novel therapeutic targets, and diagnostic methods for screening, early diagnosis, and developing better treatment modalities.

 Molecular mechanisms and gut microbiota

CRC develops on a background of IBD, which includes Crohn’s disease (CD) affecting the entire gastrointestinal (GI) tract and ulcerative colitis (UC) affecting mainly the colon and rectum. The significantly increased risk of developing CRC in IBD patients is largely attributed to the chronic inflammation associated with IBD, which can lead to dysplastic changes that can eventually progress to cancer. CRC is due to the combined effects of genetic and environmental influences on the body (discussed above). At the cellular level, chromosomal instability, characterized by a genetic abnormality that includes number alterations, indels, translocations, amplifications, and loss of heterozygosity, is responsible for 65–70% of CRC development. Chromosomal instability arises because of dysfunctional chromosomal segregation, disordered telomere viability, and ineffective DNA-damage response machinery [12]. For example, somatic mutation of the tumor suppressor gene FBXW7 (F-box and WD repeat domain containing 7) accounts for nearly 16% of CRC patients. FBXW7 mutation is associated with a higher tumor mutation burden, a higher microsatellite instability (MSI) score, and a lower chromosomal instability score. MSI is responsible for 15% of CRC cases, which is due to mismatch repair errors [12].

FBXW7 mutation with a higher MSI score results in a higher infiltration of M1 macrophage, CD8+ T cell, and regulatory T (Treg) cell and significant enrichment of interleukin (IL)-6 Janus kinase/signal transducer and activator of transcription 3 (JAK/STAT3) signaling, p53 pathway, and interferon (IFN)-γ and IFN-α response in CRC patients [13]. FBXW7β, an isoform of FBXW7, is an E3 ligase of fatty acid synthase (FASN) that, when mutated, leads to lipogenesis [14]. The increase of FASN regulates CRC metastasis by assisting in its growth and survival. FASN converts carbohydrates into fatty acids that are then converted into lipids that can either be stored or used as needed [15]. This allows the tumor to maintain its energy homeostasis and continue growing. Serrated neoplasms (a type of polyp in the colon, if left untreated, can develop into bowel cancer) make up 15–25% of CRCs, which typically arise from a BRAF gene activation, resulting in methylation of CpG islands [9, 12].

Gut microbiota research in recent years has gained traction, especially in its association with CRC. The gut microbiome is considered very important as a mediator for the pathogenesis of CRC, working as a dynamic ecosystem at the interface of genetic and environmental factors between the host. Gut microbiota is a complex community consisting of trillions of microorganisms, including bacteria, fungi, and protists, living in a symbiotic relationship with humans. They play a critical role in nutrition, protection, and digestion [16]. Though gut microbiota varies in each person, phyla Firmicutes and Bacteroidetes make up to 90% of the gut microbiome. The gut microbiota gets its nutrients from dietary carbohydrates, fermenting them to create short-chain fatty acids (SCFAs) [17]. SCFAs are known to boost the functions of Th1 and Th17 cells, which prevent and fight infection. SCFAs also increase the production of the effector cytokines IL-22 and IL-17 during active immune responses, which are key to preventing infection and fighting pathogens [18] (Figure 1). However, disruption in microbiota with a decrease in beneficial and an increase in harmful microbes, called dysbiosis, is due to a decrease in the diversity of microbiota and can cause negative effects. Dysbiosis can be caused by various factors such as genetic background, health status (infections, inflammation), and lifestyle habits. Environmental factors such as diet (high sugar, low fiber), antibiotics, drugs, food additives, and hygiene have also been shown to cause dysbiosis [19].

Risk factors and pathophysiology of CRC. Gut microbiota dysbiosis, influenced by environmental and lifestyle factors, creates a favorable environment for CRC. The presence of risk factors, including diabetes, smoking, alcoholism, chronic inflammation, and others, leads to the alteration of the intestinal microbiota termed dysbiosis. Gut dysbiosis increases the secretion of proinflammatory cytokines such as IL-6 and TNF-α, expression of TLRs, and oxidative stress by increasing the production of ROS. This disrupts the intestinal barrier and increases the propensity for CRC. Further, the presence of polyps in the intestine also increases the risk of CRC. CRC: colorectal cancer; IL: interleukin; ROS: reactive oxygen species; TLRs: toll-like receptors; TNF: tumor necrosis factor. Created in BioRender. Rai, V. (2025) https://BioRender.com/it0zune

Specific bacterial species, such as Fusobacterium nucleatum (F. nucleatum), Escherichia coli (E. coli), and Bacteroides fragilis (B. fragilis), carry genotoxins and metabolites that participate in DNA damage, activation of oncogenic pathways, and suppression of anti-tumor immune mechanisms. Also, microbiota metabolites such as SCFAs have protective effects, and secondary bile acids (SBAs) are potentially carcinogenic over the direct metabolism of primary bile acids in bacteria. This can cause IBD, obesity, diabetes mellitus, and CRC [17, 20] (Figure 1). Dysbiosis creates a microenvironment, perfect for CRC to develop. As previous studies have found a relationship between dysbiosis and CRC, not much has been utilized in the treatment and prevention of CRC. This review aims to comprehensively discuss the role of gut microbiota in CRC and potential therapeutic aspects.

 Intestinal immunity and microbiota

The GI tract serves as the interactive framework for both the gut microbiota and the gut immune system. The initial layer of the gut immune system, which includes gut-associated lymphoid tissue and Peyer’s patches, develops through essential interactions with gut commensals. This established immune barrier and its associated mechanisms restrict direct contact between commensals and the epithelial cell surface. The second layer of immunity swiftly detects and eliminates bacteria without allowing their entry into intestinal tissues. The third tier of immune responses operates within the mucosa, inhibiting the activation of the systemic immune system. The innate immune barrier consists of mucus, antimicrobial peptides (AMPs), and secretory IgA (sIgA) [21]. Chronic inflammation of the GI tract is one of the highest risk factors for developing CRC. Chronic inflammation and epithelial damage can promote DNA damage, dysplasia, and ultimately CRC. To understand how disruptions in host intestinal immunity may contribute to colorectal carcinogenesis, it is essential to examine the key components of the innate immune barrier. These include the mucus layer, AMPs, sIgA, and various innate immune cells, each plays a distinct role in maintaining intestinal homeostasis and preventing chronic inflammation. The following subsections will explore how perturbations in the host’s innate immunity contribute to the development of CRC.

Mucus layer

The mucus layer in the GI tract, composed of mucin glycoproteins from goblet cells, forms a protective, gel-like barrier on the intestinal epithelia, preventing microbial attachment and facilitating luminal content transport (Figure 2A). This layer consists of a peptide backbone with glycosylated and non-glycosylated domains, primarily featuring oligosaccharides like N-acetylglucosamine, N-acetylgalactosamine, fucose, and galactose, terminating in sialic acid or sulfate groups [22]. Besides serving as a barrier, mucins provide carbohydrates and peptides for commensals such as Bacteroides thetaiotaomicron and B. fragilis [23] and Bifidobacterium bifidum [24]. Mucolytic bacteria like Ruminococcus torques and Ruminococcus gnavus have been demonstrated to degrade mucin in vitro and enhance other nonmucolytic bacteria to utilize mucin as a nutrient source [25]. The degradation of mucin potentially contributes to the thinning of the mucus layer. Pathogens like Helicobacter pylori, Campylobacter jejuni, Salmonella spp., E. coli, and Shigella flexneri have evolved mechanisms to breach the mucus barrier, including urease production, flagella, and mucin-binding proteases [26, 27]. The depletion of the mucus layer, in addition to mechanisms that breach the mucus barrier, increases microbial-epithelial contact, promoting inflammation and mucosal damage, which can lead to symptoms characteristic of irritable bowel disease. Clinical manifestations of these events may involve persistent changes in bowel habits, rectal bleeding, or abdominal discomfort mimicking irritable bowel syndrome [26, 27].

Intestinal immunity and microbiota in gut health. (A) The mucus layer forms the first line of defense in the GI tract to prevent microbial attachment to epithelial cells. (B) Antimicrobial peptides, including defensins, cathelicidins, and C-type lectins, secreted by Paneth cells and other epithelial cells, inhibit microbes. (C) Secretory IgA traps pathogens and toxins in the mucus. Polysaccharide A and butyrate from commensal bacteria promote Treg-mediated anti-inflammatory responses. (D) Pattern recognition receptors like TLRs and NLRs detect microbial-associated molecular patterns. This triggers the immune response pathway involving MyD88, TRIF, MAPK, and NFκB to protect intestinal cells. Activation of these pathways regulates immune responses and inflammation, and the acute immune response protects the intestinal epithelium. However, in the presence of chronic inflammation, this regulation is lost and results in IBD. AMPs: antimicrobial peptides; DAMP: damage-associated molecular pattern; GI: gastrointestinal; IBD: inflammatory bowel disease; IL: interleukin; LPS: lipopolysaccharide; MAPK: mitogen-activated protein kinases; MyD88: myeloid differentiation primary response 88; NLR: NOD-like receptor; PAMP: pathogen-associated molecular pattern; TGF-β: transforming growth factor beta; TLR: Toll-like receptor; Treg: regulatory T; TRIF: TIR-domain-containing adapter-inducing interferon-β. Created in BioRender. Rai, V. (2025) https://BioRender.com/e7t5oem

 Antimicrobial peptides

AMPs such as defensins, cathelicidins, and C-type lectins are secreted by intestinal epithelial cells, including enterocytes, Goblet, and Paneth cells, to restrict microbial access to epithelia (Figure 2B). These small cationic proteins (20–40 amino acids) bind to negatively charged microbial membranes or enzymatically disrupt the cell wall. Defensins are classified into α, β, and θ types. α-Defensin, produced as pro-cryptdin and converted to mature-cryptdin by matrix metalloproteinase (MMP)-7, is essential for microbial defense [28]. Mice lacking MMP-7 cannot produce mature cryptdin and are highly susceptible to Salmonella typhimurium [29]. β-Defensin is expressed in small and large intestinal epithelia via nucleotide-binding oligomerization domain 2 (NOD2) signaling, with Nod2-deficient mice showing increased susceptibility to Listeria monocytogenes [30]. θ-Defensin is found only in rhesus macaques’ leukocytes. Cathelicidin-related antimicrobial peptide (mCRAMP), encoded by Cnlp, is restricted to colonic epithelia, with Cnlp–/– mice exhibiting increased Citrobacter rodentium adherence [31]. C-type lectins, with over 1,000 proteins, play a critical role in innate and adaptive immunity. For instance, RegIIIγ, a secreted antibacterial lectin, creates a ~50 μm zone separating microbiota from the small intestine epithelial surface [32].

Disruption of AMP expression has been associated with the development of CRC. An analysis of four independent CRC patient cohorts demonstrated a significant and consistent decrease in human β-Defensin 1 (HBD1) expression in CRC tissues. EGFR (epidermal growth factor receptor) signaling, a pathway often upregulated in CRC, represses HBD1 when activated in colon tumor tissue cell lines [33]. Human α defensin 5 (DEFA5) and DEFA6 dysregulation are also associated with CRC. DEFA5 exhibits an inhibitory effect on colon cancer cell lines, whereas DEFA6 overexpression was associated with tumorigenesis [34]. An analysis of 650 CRC tissue samples and 50 paired normal colorectal mucosa samples revealed that the colorectal tissue showed a significant reduction in expression of cathelicidin (LL-37). These findings suggest that the disruption of AMP expression contributes to CRC pathogenesis through impaired mucosal barrier function and modulation of oncogenic signaling pathways. Altered expression of AMPs may facilitate microbial dysbiosis and sustained inflammation, creating a microenvironment conducive to tumor initiation and progression. Moreover, the differential roles of specific defensins (e.g., tumor-suppressive DEFA5 vs. tumor-promoting DEFA6) highlight the complexity of AMP regulation in CRC and suggest that targeted modulation of AMP pathways could represent a novel therapeutic strategy for CRC [35].

 IgA

sIgA, a crucial defense mechanism, protects intestinal epithelia from enteric toxins and pathogens while maintaining immune tolerance (Figure 2C). In Peyer’s patches, macrophage-like C-X3-C motif receptor 1 (CX3CR1)+ dendritic cells (DCs) capture luminal antigens and transfer them to migratory CD103+ DCs, which then interact with Treg cells to induce B cells to produce IgA, aided by retinoic acid, transforming growth factor beta (TGF-β), IL-10, and thymic stromal lymphopoietin [36, 37]. The IgA produced by plasma B cells translocates to the intestinal lamina propria and across the epithelial layer, where it entraps bacteria in mucus, neutralizing toxins and pathogens, and facilitating their removal by peristaltic and mucociliary actions [38]. The balance between commensals and pathobionts influences IgA secretion, with commensal-derived polysaccharide A from B. fragilis and metabolites like butyrate inducing anti-inflammatory responses via Treg cells. In dysbiosis, certain commensals act as pathobionts, triggering pro-inflammatory responses, as seen in experimental colitis, where H. hepaticus activates TH17 cells through IL-17, IL-23, and tumor necrosis factor (TNF)-α. Malnourishment can alter the gut microbial composition and IgA responses, as demonstrated by the transfer of a malnourished infant’s IgA(+) bacterial consortium to gnotobiotic mice, which led to epithelial barrier disruption, weight loss, and sepsis, conditions preventable by administering IgA-targeted bacteria from healthy microbiota [39].

Several studies demonstrate that disruptions to IgA regulation can contribute to the development of CRC. An assessment of colon tissue from adenocarcinoma patients revealed a significant reduction in IgA-secreting plasma cells due to impaired chemokine homing signals to the mucosal tissue [40]. Igha knockout mice (Igha–/–) were observed to have increased spontaneous inflammation localized to the ileum with an increase in CD4+ T cells, elevated IFN-g and IL-17, increased ileal segmented filamentous bacteria, and perturbed gut microbiota composition [41]. In a CRC mouse model, deletion of marginal zone and B1 cell-specific protein (Mzb1–/–), resulting in IgA deficiency, demonstrated an increase in tumor nodule size and number compared to wild-type controls. Oral supplementation of monoclonal IgA in Mzb1–/– mice alleviated inflammation and CRC progression [42]. Collectively, these studies suggest IgA deficiency is associated with increased intestinal inflammation, microbial dysbiosis, and increased susceptibility to CRC, with potential avenues of IgA monoclonal antibody therapy in CRC.

 Innate and adaptive immunity

The innate immune response distinguishes between commensals and pathogens through germline-encoded pattern-recognition receptors (Figure 2D). Toll-like receptors (TLRs) identify conserved microbial-associated molecular patterns such as bacterial lipopolysaccharide (LPS), lipoproteins, flagellin, and unmethylated CpG DNA. TLR subfamilies have specific targets: TLR1, TLR2, and TLR6 recognize lipids, while TLR7, TLR8, and TLR9 recognize nucleic acids; TLR5 identifies flagellin, and TLR4 can recognize diverse ligands like LPS and paclitaxel [43]. Cytosolic antigens, including γ-D-glutamyl-meso-diaminopimelic acid and muramyl dipeptide, are recognized by NOD-like receptors [44, 45]. Antigen-presenting cells like DCs and macrophages express TLRs, ingest and degrade pathogens, and produce co-stimulatory molecules and cytokines. These cytokines aid in differentiating naive CD4+ T cells into various subsets, including T helper 1 (TH1), TH2, TH17, Treg, and TR1 cells. A balance between Treg cells and CD4+ effector T cells in the intestinal mucosa helps discriminate between commensal and pathogenic microbes. Microbial dysbiosis can trigger an inflammatory response mediated by TH1, TH2, and TH17 cells. TH1 and TH2 activation is marked by pro-inflammatory cytokines like IL-4, IL-5, IFN-γ, and IL-13, while TH17 cells produce IL-17, which stimulates stromal cells to express pro-inflammatory cytokines such as IL-6, IL-8, and IL-22 [46, 47].

TLRs and NOD-like receptors have been reported to be associated with modulating CRC risk. Strong upregulation of TLR4 in colonic tissues has been associated with the progression of UC and CRC [48]. Deletion of TLR4 protected TLR4–/– mice from tumor progression [49]. Similarly, the inhibition of TLR4 signaling pathways also attenuated intestinal inflammation and impeded tumorigenesis in the colon of BALB/c mice [50]. TLR9 was also found to be upregulated in a CRC mouse model [51]. Inhibiting TLR9 in the CRC cell line HT29 decreased the cell viability and proliferation of CRC cells. Polymorphisms in TLR2, 3, 4, 5, and 9 have been reported to modulate CRC risk and development in humans. Nod2 deficiency in Nod2–/– mice significantly enhanced inflammatory pathways and epithelial cell proliferation in hyperplastic regions, indicating Nod2-deficient mice are highly susceptible to CRC [51–53]. Together, these findings indicate dysregulation of TLR and NOD-like receptor signaling can disrupt intestinal homeostasis and inflammation-induced colorectal tumorigenesis.

 Factors affecting microbiota and dysbiosis in IBD

Dysbiosis, an alteration in the gut microbiota, is influenced by numerous factors, including diet, age, genetics, peristalsis, immune responses, antibiotics, nonantibiotic drugs to treat diabetes, the mode of delivery at birth, the method of infant feeding, stress, psychological situations, exercise, and geographical location [54–58]. Further, ethnicity, living with pets (dogs and cats), alcoholism, recreational drugs, environmental pollution, food additives, smoking, and extraintestinal diseases also influence gut microbiota [59]. In addition, any alterations in intestinal defense mechanisms, including the mucus layer, IgA, AMPs, and microRNA (as discussed above), may also contribute to dysbiosis. It can compromise intestinal mucosa integrity and permeability, triggering MALT (Mucosal Associated Lymphatic Tissue) activation, inflammation (leukocytes, cytokines, TNF-α), and tissue damage [60].

Dysbiosis is linked to diseases like type 2 diabetes, allergies, fatty liver disease, obesity, and IBD [61]. For example, Roseburia intestinalis and Faecalibacterium prausnitzii were found to be lower, while Lactobacillus gasseri, Streptococcus mutans, Proteobacteria, and certain Clostridiales were higher in individuals with type II diabetes. An increase in Lactobacillales, mainly Streptococcus species, and a decrease in species belonging to Bacteroides, Eubacterium, and Clostridium were reported in individuals with higher HbA1C (glycated hemoglobin) [57]. In CRC, a handful of bacterial species have been highly implicated due to their production of genotoxic substances [62]. For instance, genetic analysis of the microbiomes collected from colorectal carcinomas continuously reveals elevated levels of F. nucleatum, F. mortiferum, and F. necrophorum within both primary tumor sites and metastasis [63]. It has been postulated that the Fusobacterium species contributes to CRC progression by utilizing a galactose adhesion hemagglutinin molecule known as Fusobacterial Fap2 that then binds galactose-N-acetyl-d-galactosamine within tumor cells [64]. Upon infiltration of tumor cells, Fusobacteria utilize their virulence factor, FadA, to support CRC growth. Fusobacterium species also indirectly contribute to the pathogenesis of CRC due to their linkage with known risk factors, namely IBD [63].

The pathogenesis of IBD involves microbiota changes, immune responses, genetic factors, environmental factors, surgery, lifestyle, hygiene, diet, and drugs [65–67]. A Western-style diet rich in fats and refined sugars can increase ROS (reactive oxygen species) production, inflammation, and dysbiosis via fewer Firmicutes and increased Enterobacteriaceae (dysbiosis) [68]. Crohn’s disease patients specifically show reduced Faecalibacterium prausnitzii (Firmicutes), crucial for butyric acid production [69]. Intestinal dysbiosis, at a molecular level, leads to an altered production of microbial metabolites such as SCFAs, LPS, and bile acids, disrupting intestinal barrier function, impacting host physiology, and inducing inflammation. Transgenic mouse models reveal that essential SCFAs such as acetate and butyrate help maintain intestinal homeostasis via signaling through G protein-coupled receptors such as GPR43 that then initiate signal cascades [70]. Ultimately, intestinal barrier disruption causes increased intestinal permeability due to decreased expression of tight junction proteins (leaky intestine) (Figure 3). Increased LPS activates immune cells like macrophages and DCs, involving TLRs, contributing to increased secretion of pro-inflammatory cytokines. Dysbiosis may also contribute to altered gene expression through epigenetic modification involving methylation and histone modification, potentially altering the host response to microbial signals [19, 71–74] (Figure 3).

Molecular changes in intestinal dysbiosis contributing to IBD. Gut dysbiosis, an imbalance in the gut microbiota, significantly increases the risk of developing IBD, which is characterized by chronic inflammation in the gut. This imbalance can lead to a breakdown of the intestinal barrier, allowing harmful bacteria to penetrate the lining and trigger inflammation. Inflammation is mediated by increased recruitment of immune cells secreting pro-inflammatory cytokines. A decrease in anti-inflammatory cytokines and growth factors, an increase in oxidative stress, and activation of inflammatory mediators such as TLRs contribute to the chronicity of inflammation and the development of IBD. CRP: C-reactive protein; IBD: inflammatory bowel disease; IL: interleukin; MPO: myeloperoxidase; NLRP3: NOD-, LRR-, and pyrin domain-containing protein 3; ROS: reactive oxygen species; TGF: transforming growth factor; TLRs: toll-like receptors; TNF: tumor necrosis factor; Treg: regulatory T. Created in BioRender. Rai, V. (2025) https://BioRender.com/lumhuep

 Gut microbiota and colorectal cancer

The gut microbiota’s role in the progression from adenoma to carcinoma has been suggested, with a healthy microbiota correlating with a lower risk of advanced adenoma [75]. Factors such as obesity, high-fat diets, smoking, and alcohol consumption, which affect the gut microbiota, are also linked to colon carcinogenesis [76]. As compared to healthy individuals, CRC patients show reduced bacterial diversity and abundance, particularly of Firmicutes and Bacteroidetes [77]. Gut microbiota influences CRC. The gut microbiota of patients with CRC differs from healthy subjects’ microbiota as they have a lower abundance of commensal bacteria and a higher abundance of carcinogenic bacteria [78]. Certain Bacteroides spp. correlates with systemic inflammation and tumor stage [79]. The three most common bacteria seen in CRC patients are F. nucleatum, E. coli, and B. fragilis [78]. Streptococcus gallolyticus and enterotoxigenic B. fragilis (ETBF) are associated with CRC onset and progression [80].

F. nucleatum is typically part of the oral microbiota; however, in CRC patients, it is found in the gut [81]. F. nucleatum is correlated with age, tumor diameter, and poor prognosis in metastatic CRC, making it a potential biomarker for proximal colon cancer prognosis. F. nucleatum not only correlates with clinical features but also actively modulates the tumor microenvironment by interfering with host immune responses [82]. F. nucleatum expression was related to MSI and BRAF mutation and was detected in 56% of malignant cases compared with benign lesions. The presence of F. nucleatum is also linked to increased infiltration of TIGIT-positive immune cells within the tumor, which are often functionally suppressed, contributing to an immunosuppressive microenvironment compared with benign lesions [79]. F. nucleatum can inhibit natural killer (NK) cells and cytotoxic T lymphocytes (CTLs), essential for tumor cell elimination. This is mediated by the Fap2 protein on the bacterial surface, binding to the T cell immunoglobulin and ITIM domain (TIGIT) receptor on NK cells and some T cells. Engagement of TIGIT by Fap2 leads to the recruitment of phosphatases such as SHIP1, resulting in the suppression of PI3K/Akt signaling pathways necessary for NK cell activation and cytotoxicity. As a result, the ability of these immune cells to recognize and destroy tumor cells is markedly reduced. Additionally, F. nucleatum can interact with other inhibitory receptors, such as CEACAM1 and Siglec-7, further dampening anti-tumor immune responses [79]. The colon flora is predominantly E. coli, and when it spreads to other regions of the gut, it can lead to diseases such as IBD, a contributing factor to CRC. Enteropathogenic E. coli (EPEC) is commonly found in CRC patients, and this bacterium suppresses the expression of MMR, a DNA mismatch repair protein, contributing to the development of CRC [83]. B. fragilis makes up a very small percentage of total gut microbiota; however, an increase in this bacterium has been seen in IBD, such as Crohn’s [84]. B. fragilis releases a toxin that causes inflammatory diarrhea and inflammation-related tumorigenesis [79].

Streptococcus gallolyticus has tumor-promoting effects on colon cells, increasing levels of β-catenin, c-Myc, and PCNA, which are associated with cancer development [85]. The higher levels of this bacterium in CRC patients are sustained by CRC-specific conditions such as increased bile acids. ETBF, often linked to diarrhea, peritonitis, and sepsis, has a positive correlation with active IBD and CRC [86]. Co-colonization of toxigenic E. coli and ETBF in mice leads to increased IL-17 production and DNA damage, accelerating CRC development [87]. ETBF’s toxin can induce c-myc expression, IL-8 secretion, and STAT3/Th17 immune response activation, further increasing CRC risk [86].

 Dysbiosis and metabolites as biomarkers

Emerging evidence suggests gut microbiota-derived metabolic profiles can provide predictive insights on CRC development. However, a challenge arises in interpreting whether these findings are causative, consequential, or incidental to CRC progression. Serum metabolites analysis in CRC and adenoma patients, 885 serum metabolites were identified to be significantly altered, with 8 gut microbiome-associated metabolites [88]. The study reported a significantly increased B. fragilis, F. nucleatum, Parvimonas micra (P. micra), and Campylobacter jejuni and downregulation of Bifidobacterium longum (B. longum) in colorectal patients. Out of 855 colorectal abnormal correlated metabolites, 322 metabolite features exhibited a significant association with the gut microbiome, including F. nucleatum, P. micra, Alistipes finegoldii, Odoribacter splanchnicus, B. longum, and Parabacteroides distasonis [88]. While this study illustrates potential microbe-metabolite associations, it remains correlative, and the temporal dynamics of these changes remain unclear.

A cross-sectional, observational, multi-omics study investigated the temporal dynamics of the metabolome of patients with early-onset CRC (EO-CRC) and late-onset CRC (LO-CRC) [89]. In this study, a comparative metabolic and metagenomic analysis on a discovery cohort comprising 114 EO-CRC patients, 130 LO-CRC, and age-matched healthy controls (97 LO-controls and 100 EO-controls) was performed. Additionally, an independent validation cohort was also included. Both patient groups demonstrated reduced alpha diversity in gut microbiota composition, but EO-CRC patients were observed to have elevated tryptophan, bile acids, and choline production, metabolites with known roles in inflammation and oncogenesis. Conversely, LO-CRC patients demonstrated reduced SCFA production, microbial-produced GABA (gamma-aminobutyric acid) production, and increased acetyl-CoA. While this study demonstrates distinct etiological pathways, causation is yet to be established.

Attempts to distinguish the gut metabolome of colorectal adenoma (CRA) from CRC have also been investigated [90]. In an analysis of fecal and serum metabolites of CRA, CRC, and healthy patients, butyric acid was significantly higher in patients with CRA than in healthy patients. Additionally, healthy patients were enriched with α-linoleic acid and lysophosphatidylcholine, while significantly reduced in patients with CRC. These findings suggest that metabolites may serve as biomarkers for the type and staging of CRC. However, the findings are preliminary, and additional studies with larger, diverse cohorts are required for reproducibility and utility of these biomarkers.

Mechanistic studies may provide insight into the functional consequences of altered microbial metabolites. In the context of CRC, gut metabolites could elicit pro-oncogenic or anti-tumorigenic responses. SBAs derived from microbial transformation of hepatic bile acids are shown to be pro-oncogenic by reshaping the gut microbiota, reducing microbial diversity, suppressing CD8 T cell function, and dysregulating the Wnt pathways implicated in cell proliferation. SFCA, such as butyrate, produced by dietary fiber fermentation, supports colonocyte energy metabolism, maintains luminal hypoxia, and regulates epithelial homeostasis [91–95]. SCFAs reduce the expression of various genes involved in cell proliferation and growth in a human colorectal cell line [96]. CRCs with MSI, when exposed to SCFA, are primed to induce greater CD8+ T cell activation and enhance antitumor activity [97]. Gut microbiota-produced indole derivatives have also been shown to provide protective effects against CRC. Indole-3-lactic acid derived from Lactobacillus plantarum has been shown to ameliorate tumor growth, intestinal inflammation, and gut dysbiosis by improving tumor-infiltrating CD8+ T cell activity by decreasing their cholesterol levels through the downregulation of Serum amyloid A3 (Saa3), a key gene involved in cholesterol metabolism [98].

These studies provide a valuable framework for future research to develop clinically useful diagnostic markers. Clinical translation of these diagnostic markers would require integrative, longitudinal studies that incorporate mechanistic validation, host-microbe interactions, and multi-omics approaches.

 Targeting microbiota in IBD Microbiota and tumor treatment

Modulation of the gut microbiota and gut microbiota-derived metabolites has been shown to augment antitumor treatment. In a mouse study, phage-induced inhibition of tumor-associated gut microbe F. nucleatum enhanced the efficacy of first-line chemotherapy drugs [99]. Conversely, altered microbiota due to chemotherapy may also confer resistance to chemotherapeutic drugs. In a longitudinal study, 16S rRNA sequencing on 353 fecal specimens exhibited reduced microbial diversity after neoadjuvant chemoradiotherapy (nCRT) [100]. The investigators found that nCRT-induced enrichment of Bacteroides vulgatus (B. vulgatus), leading to B. vulgatus-mediated nucleotide biosynthesis, protected cancer cells with upregulated DNA repair and nucleoside transport genes. These findings were confirmed in the same study when nucleoside supplementation or B. vulgatus gavage protects cancer cells from the 5-fluorouracil or irradiation treatment [100].

Metabolites of microbiota, for example, indole-3-carboxaldehyde (I3A) and indole-3-propionic acid (IPA), have been proven in their abilities to reduce inflammation, support recovery of blood-forming organs, decrease bone marrow suppression, enhance GI function, and maintain the structure of the GI tract, even after radiation exposure [101]. In the same way, SCFAs produced by microbiota act against radiotherapy in the restoration of the epithelial barrier and overall gut integrity through mechanisms of, for example, HIF-1 expression and regulation of tight junctions, along with increased mucin production [102]. Conversely, dysbiosis of gut microbiota can worsen radiation enteritis by inducing epithelial inflammation and the malfunction of the barrier and increasing the expression of pro-inflammatory cytokines such as TNF-α and IL-1β [103].

Also, the modulation of gut microbiota affects the responses to treatments that are related to immune actions. The gut flora shapes the host immune responses in the tumor microenvironment, which is mediated by both innate and adaptive immune mechanisms and influences the effects of the immune checkpoint inhibitors, including PD-1/PD-L1 blockers. For example, the antibiotic-treated patients demonstrate less effect from PD-1 blockers; however, this insensitivity could be reversed by fecal flora transplantation [104]. F. nucleatum upregulates the succinate production that induces tumor cell immune resistance against anti-PD-1 monoclonal antibody treatment, while its elimination resensitizes tumor cells to this treatment [105]. Other interventions that render soluble fiber pectin as a probiotic food source have been shown to increase the efficacy of anti-PD-1 therapy under the preclinical setting through finding increased secretions of the metabolite indole-3-carboxylic acid by Lactobacillus gallinarum [106, 107]. Changes in gut bacteria and their by-products have been proven to increase the effectiveness of the treatment in several ways. Some bacteria, for instance, Salmonella typhimurium, can enter and grow in tumors because these tumors create a weak defense area around them. These bacteria then kill the tumor cells by destroying blood vessels through TNF-α, and also activate immunity signaling in the tumor cell to stimulate macrophage phagocytosis and autophagy in the tumor cell itself [108]. In mice, making a certain group of tumor-promoting bacteria from the gut, F. nucleatum, less active with viruses increased the effect of the common chemotherapy drugs. However, treatment-related changes in the flora may sometimes result in bacterial resistance against the medications. For example, the increase of an ordinary gut bug such as B. vulgatus leads to the increased synthesis of nucleotides after the combined radiation and medicament therapy before surgery, and this feeds the tumor cell with more DNA-repair and nucleoside-transporting genes. Further, nucleoside feeding or feeding of B. vulgatus protects cancer cells against irradiation with 5-FU. Also, F. nucleatum may help chemoresistance by targeting TLR4 and MYD88 (myeloid differentiation primary response 88) innate immune signaling, and some specific microRNAs to activate the autophagy pathway. Thereby reducing apoptosis and altering the response of CRC cells to chemotherapy [109].

Apart from this, bacterial CpG-ODN can cause an innate immune response resulting in TNF-α driven hemorrhagic necrosis and also leading to adaptive immunity wherein both CD8+ and CD4+ T cells cooperate to eliminate tumors. For instance, the BCG (bacille Calmette-Guerin) vaccine works against tumors by using CD4 T cells and interferon-γ signaling, not via MHC-II (major histocompatibility complex class II) restriction [110]. Altogether, these findings highlight the dual role of the gut microbiota in cancer therapy, where specific bacterial species and their metabolites can either hinder or enhance the efficacy of conventional and emerging treatments. Targeted microbiota manipulation through phage therapy, antibiotics, fecal transplants, or diets is a hopeful plan to fight tumors and improve patient outcomes.

 Improving microbiota while on colorectal cancer therapies

Targeting microbiota to improve treatment for CRC is still a novel strategy. Treatment for CRC depends on multiple factors, including the cancer stage and the age of the patient. Current treatment for CRC typically involves chemotherapy, surgery, radiotherapy, immunotherapy, and other modalities [111]. Non-metastatic CRC is typically resected with surgery followed by chemotherapy. Surgery is seen as a curative measure; however, 35% of patients will have the cancer recur and eventually metastasize [112]. At initial diagnosis, CRC has metastasized in 22% of patients [113]. For metastatic CRC, treatment typically involves chemotherapeutic drugs of 5-fluorouracil, capecitabine, irinotecan, and oxaliplatin, along with folinic acid. Unfortunately, chemotherapy can lead to more problems, as CRC cells can become resistant to it [5]. Because of the interaction of microbiota and CRC, therapies involving it have gained more traction. Current therapies for CRC, including chemotherapy and radiotherapy, have been proven to affect microbiota as they reduce the diversity of the microbiota, which can affect patient outcomes to treatment [114]. However, currently, there are no therapies to improve microbiota while on anticancer treatment. A clinical trial, focusing on prebiotics, is exploring the effect of xylooligosaccharides (XOS) on CRC patients receiving chemotherapy. The aim is to assess whether prebiotics can increase the bioavailability of cytotoxic drugs, reduce adverse effects, and improve the quality of life by modifying gut microbiota. XOS feeds beneficial bacteria such as bifidobacteria and lactobacilli within the digestive tract [115]. Currently, the potential of FMT (fecal microbial transplant) is being discussed, but it has not been utilized for CRC patients.

The microbiota is a complex, diverse community unique to every person. It consists of both good and bad bacteria, protists, and fungi. Because it has such an intimate relationship with its host, a rise in certain bacteria can lead to detrimental effects. It has been shown that patients with CRC have dysbiosis, and finding solutions to improve it can lead to better outcomes. Finding the microbiota is uniquely diverse, and finding the correct bacteria that will benefit the patient without causing more adverse effects is difficult. Introducing prebiotics to a patient undergoing chemotherapy may lead to a risk of infection as chemotherapy weakens the immune system. Fecal matter transplantation theoretically shows potential, but more studies will have to be done to show its effectiveness for CRC patients. Currently, plenty of data shows the potential of utilizing microbiota to improve CRC outcomes. However, it is still early in its development, and clinical research has just started.

Probiotics/Prebiotics

Probiotics can modulate host microbiomes due to their presence within the GI tract. Previous studies supported that postoperatively, probiotics successfully decreased rates of infection [116]. Yet, the role played by probiotics in the process of oncogenesis remains debatable in terms of its benefits and risks. Franko et al. [116] investigated the interplay between the microbiome and CRC therapy in a double-blind trial with short-course perioperative oral probiotics in 120 patients undergoing major GI surgery. In the study, 57 patients were prescribed oral probiotic VSL #3 (a probiotic consisting of strains of Bifidobacteria, Lactobacillus, and Streptococcus), and 63 patients, a placebo [116]. The probiotic and placebo were dispensed simultaneously in both groups, with patients receiving one dose preoperatively and two doses per day postoperatively until being discharged, with a maximum of 15 doses. After a follow-up of six years, the results showed no statistical difference (p = 0.317) in survival between the two groups, suggesting that probiotics did not make any difference in the survival rate of patients diagnosed with curable CRC. These results suggest that probiotics do not have systemic anti-cancer effects, although they have effects at the local microbiome level [116]. Data from mouse models support such conclusions by showing that certain strains have benefits. For instance, Lactobacillus JY300-8 and JMR-01 reduced the incidence of CT26 tumors to between 13% and 17% in both the live and inactivated forms, indicating that there are direct anti-tumor effects irrespective of the viability of the cells [117]. In this study, CRC was induced in the CT26 cells of mice that received the probiotics and those that didn’t, i.e., the control group. Another layer of complexity was added in that the two probiotics were administered with either living or inactivated bacteria. While the control group developed tumors at a rate of 97%, the mice given living and inactivated bacteria only developed tumors at a rate of 13% and 17%, respectively [117]. These outcomes strongly support the administration of probiotics containing Lactobacillus to reduce tumorigenesis in CRC. Clinically, such probiotics as Colon Dophilus alleviate chemotherapy-induced diarrhea and enterocolitis, hence indirectly giving them a possibility of making the treatment tolerable [118].

Prebiotics such as Simbio-flora also showed promising results in CRC patients who underwent tumor resection. Prebiotics like Simbio-flora, which enrich Lactobacilli and Bifidobacterium lactis HN019, shorten hospital stay and reduce postoperative inflammation in CRC patients [119]. While these diverse outcomes underscore the many benefits that both prebiotics and probiotics possess in the treatment of CRC, further investigation and validation of strain and dose are warranted [120].

 Fecal transplant

FMT acts as a strategy to ameliorate dysbiosis and increase CRC therapy. The Chinese herbal remedy known as Xiao-Chai-Hu-Tang (XCHT) has traditionally been used to treat depressive symptoms, which are known to contribute to tumorigenesis [121]. In this study, xenograft mice under chronic stress and treated with XCHT [includes Bupleurum root (Chai Hu), Pinellia tuber (Ban Xia), Scutellaria root (Huang Qin), Ginseng (Ren Shen), Jujube (Da Zao), Licorice (Gan Cao), and Ginger (Sheng Jiang)] reduce the tumor volume by 60%. The underlying mechanism was inhibition of antiapoptotic proteins Bcl-2/Bcl-xL [121]. This was attributable to the fact that the FMTs containing XCHT increased the concentration of various LPS-producing bacteria, including Desulfovibrio. FMT can also transfer antitumor immune cells that are enriched with B. vulgatus, increased CD8+ cells, and NK cells in murine CRC models with an elevation of TNF-α and IFN-γ levels [122]. Translating these results in humans is important; however, variations between mouse models and humans due to differences in the microbiota are of concern. The host-donor response hinted by preclinical data to be ideal in the acquisition of beneficence is hindered by the change in microbiota and undermines human real-life application [123]. The earliest trials uncovered that it may have a potential application in the attenuation of colitis secondary to immune checkpoint inhibitors. However, larger studies are needed to determine the role of this therapy in the primary treatment of CRC [124].

 Diet

The gut microbiome plays an essential role in host metabolism as bacteria break down various non-digestible compounds. Improper diet can therefore contribute to poor health outcomes due to changes in the intestinal mucosa and increased inflammation. The consumption of large amounts of processed red meats contributes to CRC due to the production of N-nitroso compounds that disrupt the intestinal lining [125]. Similarly, high-fat diets increase the concentration of lysophosphatidic acid, thus disrupting normal metabolism and contributing to tumorigenesis [126]. Meanwhile, large amounts of fiber help increase the concentration of bacterial species such as Bifidobacteria and Lactobacillus, leading to increased butyrate levels that help suppress tumor growth [125]. The role of these two species has been documented in previous studies in which the fecal microbiota of healthy participants was analyzed via fluorescent in situ hybridization [127]. Participants were instructed to consume First Leaf (blackcurrant extract powder, lactoferrin, and lutein) and Cassis Anthomix 30 (blackcurrant extract powder; either 672 mg/day or 1,500 mg/day), which both contained blackcurrant extract powder, while the former also contained lactoferrin and lutein. Interestingly, the results equated the two compounds to probiotics as they each helped increase the concentration of beneficial bacteria, including Lactobacilli and Bifidobacteria [127]. If studies such as this solidify the relevance of a healthy diet for its preventative nature, then one could similarly question its positive impact throughout CRC treatment. This has been the case for patients prescribed the chemotherapeutic drug 5-fluorouracil when administered in concert with vitamin B6 and pyrimidines. When the two nutrients are consumed in large quantities, they disrupt bacterial metabolism of folate, thus altering folate metabolism and the effects of 5-fluorouracil. Similarly, diet can alter the host microbiota in patients administered cytostatic drugs like fluoropyrimidines during their treatment of CRC [125].

The benefits that come with incorporating a healthy diet during treatment are profound and should be maintained even if patients are declared cancer-free. The findings of randomized clinical trials involving patients previously diagnosed with adenomas prove that calcium supplementation decreased rates of adenoma recurrence [128]. The trials proved that supplementation results in increased calcium levels within extracellular spaces, which then activate calcium-sensing receptors responsible for mediating interactions between microbiota and immune responses [128]. Given the rich source of calcium within milk, studies have revealed that other dairy products, such as conjugated linoleic acid, reduce carcinogenesis [129]. However, the relationship between food and cancer is not so clear-cut; for instance, evidence shows that consumption of large amounts of fermented milk products can negatively alter gut microbiota and propel CRC [128]. Even though this echoes a theme that defining certain foods as purely protective or harmful is tricky, there exists a consensus that the following are protective: milk, cheese, fruits, and whole grains, amongst others, including moderate amounts of wine. In contrast, high-risk foods include red meat, processed meat, high fructose corn syrup, animal-derived fat, and high levels of alcohol consumption [130]. The research regarding diet and tumorigenesis is still incomplete, and conscious dieting possesses great potential for the future of CRC prevention.

 Antibiotics

A patient’s microbiota can be improved throughout their treatment of CRC by selectively removing harmful species. One of the key bacterial species associated with CRC is Fusobacterium, while Bacteroides, Selenomonas, and Prevotella also prevail with metastasis. Previous studies on xenografted mice show that treatment with the antibiotic metronidazole was shown to successfully reduce the concentration of Fusobacterium, which had the additional effect of minimizing cancer cell proliferation as well as tumor growth [131]. When administered preoperatively, antibiotics were shown to enhance CRC patient survival by roughly 25% [132]. With regards to mouse models, the formulation and administration of an antibiotic known as silver-tinidazole encapsulated in liposomes (LipoAgTNZ) helped eliminate tumor-associated bacteria [132]. More specifically, the antibiotic reduced the F. nucleatum load as well as E. coli Nissle spp., all without causing dysbiosis. By targeting F. nucleatum, LipoAgTNZ enhanced survival rates by 70% within two different CRC models, thus underscoring the benefits that antibiotics possess for a host’s microbiota throughout his or her treatment.

 Conclusions

The intricate interplay between gut microbiota and CRC underscores a complex and evolving landscape of disease mechanisms and potential therapeutic strategies. Dysbiosis, marked by alterations in microbial composition and function, has been implicated in CRC pathogenesis through its effects on immune responses, mucosal integrity, and microbial metabolite profiles. The gut microbiota’s role in CRC progression highlights both harmful and beneficial aspects, with certain bacteria promoting inflammation and tumorigenesis, while others exhibit protective effects through metabolite production. Emerging evidence suggests that gut microbiota can serve as valuable biomarkers for CRC detection and progression, with specific metabolites and microbial profiles offering insights into disease stages and therapeutic responses. The modulation of gut microbiota, through interventions such as probiotics, prebiotics, and dietary changes, presents a promising avenue for enhancing CRC treatment outcomes. As research advances, a more nuanced understanding of microbial interactions and their impact on treatment efficacy will be crucial for developing personalized and effective therapeutic approaches. Future studies should continue to explore the mechanistic pathways linking dysbiosis with CRC, aiming to harness the microbiota for innovative treatment strategies and improved patient outcomes.

 Abbreviations AMPs

antimicrobial peptides

 CRA

colorectal adenoma

 CRC

colorectal cancer

 DCs

dendritic cells

 DEFA5

α defensin 5

 EO-CRC

early-onset colorectal cancer

 ETBF

enterotoxigenic B. fragilis

 FASN

fatty acid synthase

 FBXW7

F-box and WD repeat domain containing 7

 FMT

fecal microbial transplant

 GI

gastrointestinal

 HBD1

human β-Defensin 1

 IBD

inflammatory bowel disease

 IFN

interferon

 IL

interleukin

 LipoAgTNZ

silver-tinidazole encapsulated in liposomes

 LO-CRC

late-onset colorectal cancer

 LPS

lipopolysaccharide

 MMP

matrix metalloproteinase

 MSI

microsatellite instability

 Mzb1

marginal zone and B1 cell-specific protein

 nCRT

neoadjuvant chemoradiotherapy

 NK

natural killer

 NOD2

nucleotide-binding oligomerization domain 2

 SBAs

secondary bile acids

 SCFAs

short-chain fatty acids

 sIgA

secretory IgA

 STAT3

signal transducer and activator of transcription 3

 TH1

T helper 1

 TLRs

Toll-like receptors

 TNF

tumor necrosis factor

 Treg

regulatory T

 UC

ulcerative colitis

 XCHT

Xiao-Chai-Hu-Tang

 XOS

xylooligosaccharides

 Declarations Author contributions

GS, ZC, AB, and KS: Conceptualization, Methodology, Writing—original draft. VR: Writing—review & editing. All authors have read and agreed to the published version of the manuscript.

 Conflicts of interest

The authors declare no conflict of interest.

 Ethical approval

Not applicable.

 Consent to participate

Not applicable.

 Consent to publication

Not applicable.

 Availability of data and materials

Not applicable.

 Funding

Not applicable.

 Copyright

© The Author(s) 2025.

 Publisher’s note

Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.

 Siegel RL Wagle NS Cercek A Smith RA Jemal A Colorectal cancer statistics, 2023 CA Cancer J Clin 2023 73 233 54 10.3322/caac.21772 36856579 Ionescu VA Gheorghe G Bacalbasa N Chiotoroiu AL Diaconu C Colorectal Cancer: From Risk Factors to Oncogenesis Medicina (Kaunas) 2023 59 1646 10.3390/medicina59091646 37763765 PMC10537191 Abualkhair WH Zhou M Ahnen D Yu Q Wu X Karlitz JJ Trends in Incidence of Early-Onset Colorectal Cancer in the United States Among Those Approaching Screening Age JAMA Netw Open 2020 3 e1920407 Erratum in: JAMA Netw Open. 2020;3:e201038. 10.1001/jamanetworkopen.2019.20407 32003823 PMC7042874 Han CJ Yang GS Syrjala K Symptom Experiences in Colorectal Cancer Survivors After Cancer Treatments: A Systematic Review and Meta-analysis Cancer Nurs 2020 43 E132 58 10.1097/NCC.0000000000000785 32000174 PMC7182500 Shin AE Giancotti FG Rustgi AK Metastatic colorectal cancer: mechanisms and emerging therapeutics Trends Pharmacol Sci 2023 44 222 36 10.1016/j.tips.2023.01.003 36828759 PMC10365888 Hossain MS Karuniawati H Jairoun AA Urbi Z Ooi DJ John A et al. Colorectal Cancer: A Review of Carcinogenesis, Global Epidemiology, Current Challenges, Risk Factors, Preventive and Treatment Strategies Cancers (Basel) 2022 14 1732 10.3390/cancers14071732 35406504 PMC8996939 Sawicki T Ruszkowska M Danielewicz A Niedźwiedzka E Arłukowicz T Przybyłowicz KE A Review of Colorectal Cancer in Terms of Epidemiology, Risk Factors, Development, Symptoms and Diagnosis Cancers (Basel) 2021 13 2025 10.3390/cancers13092025 33922197 PMC8122718 Fritz CDL Otegbeye EE Zong X Demb J Nickel KB Olsen MA et al. Red-flag signs and symptoms for earlier diagnosis of early-onset colorectal cancer J Natl Cancer Inst 2023 115 909 16 10.1093/jnci/djad068 37138415 PMC10407716 Harada S Morlote D Molecular Pathology of Colorectal Cancer Adv Anat Pathol 2020 27 20 6 10.1097/PAP.0000000000000247 31503031 Ladabaum U Dominitz JA Kahi C Schoen RE Strategies for Colorectal Cancer Screening Gastroenterology 2020 158 418 32 10.1053/j.gastro.2019.06.043 31394083 Han C Wu F Xu J Effectiveness of sigmoidoscopy or colonoscopy screening on colorectal cancer incidence and mortality: a systematic review and meta-analysis of randomized controlled trial Front Oncol 2024 14 1364923 10.3389/fonc.2024.1364923 38549924 PMC10972922 Chan DKH Buczacki SJA Tumour heterogeneity and evolutionary dynamics in colorectal cancer Oncogenesis 2021 10 53 10.1038/s41389-021-00342-x 34272358 PMC8285471 Liu Y Chen H Bao H Zhang J Wu R Zhu L Comprehensive characterization of FBXW7 mutational and clinicopathological profiles in human colorectal cancers Front Oncol 2023 13 1154432 10.3389/fonc.2023.1154432 37064111 PMC10091464 Wei W Qin B Wen W Zhang B Luo H Wang Y et al. FBXW7β loss-of-function enhances FASN-mediated lipogenesis and promotes colorectal cancer growth Signal Transduct Target Ther 2023 8 187 10.1038/s41392-023-01405-8 37202390 PMC10195794 Li B Mi J Yuan Q Fatty acid metabolism-related enzymes in colorectal cancer metastasis: from biological function to molecular mechanism Cell Death Discov 2024 10 350 10.1038/s41420-024-02126-9 39103344 PMC11300464 Quaglio AEV Grillo TG De Oliveira ECS Di Stasi LC Sassaki LY Gut microbiota, inflammatory bowel disease and colorectal cancer World J Gastroenterol 2022 28 4053 60 10.3748/wjg.v28.i30.4053 36157114 PMC9403435 Rinninella E Raoul P Cintoni M Franceschi F Miggiano GAD Gasbarrini A et al. What is the Healthy Gut Microbiota Composition? A Changing Ecosystem across Age, Environment, Diet, and Diseases Microorganisms 2019 7 14 10.3390/microorganisms7010014 30634578 PMC6351938 Kim CH Complex regulatory effects of gut microbial short-chain fatty acids on immune tolerance and autoimmunity Cell Mol Immunol 2023 20 341 50 10.1038/s41423-023-00987-1 36854801 PMC10066346 Hrncir T Gut Microbiota Dysbiosis: Triggers, Consequences, Diagnostic and Therapeutic Options Microorganisms 2022 10 578 10.3390/microorganisms10030578 35336153 PMC8954387 DeGruttola AK Low D Mizoguchi A Mizoguchi E Current Understanding of Dysbiosis in Disease in Human and Animal Models Inflamm Bowel Dis 2016 22 1137 50 10.1097/MIB.0000000000000750 27070911 PMC4838534 Adak A Khan MR An insight into gut microbiota and its functionalities Cell Mol Life Sci 2019 76 473 93 10.1007/s00018-018-2943-4 30317530 PMC11105460 Johansson MEV Phillipson M Petersson J Velcich A Holm L Hansson GC The inner of the two Muc2 mucin-dependent mucus layers in colon is devoid of bacteria Proc Natl Acad Sci U S A 2008 105 15064 9 10.1073/pnas.0803124105 18806221 PMC2567493 Xu J Bjursell MK Himrod J Deng S Carmichael LK Chiang HC et al. A genomic view of the human-Bacteroides thetaiotaomicron symbiosis Science 2003 299 2074 6 10.1126/science.1080029 12663928 Ruas-Madiedo P Gueimonde M Fernández-García M de los Reyes-Gavilán CG Margolles A Mucin degradation by Bifidobacterium strains isolated from the human intestinal microbiota Appl Environ Microbiol 2008 74 1936 40 10.1128/AEM.02509-07 18223105 PMC2268317 Png CW Lindén SK Gilshenan KS Zoetendal EG McSweeney CS Sly LI et al. Mucolytic bacteria with increased prevalence in IBD mucosa augment in vitro utilization of mucin by other bacteria Am J Gastroenterol 2010 105 2420 8 10.1038/ajg.2010.281 20648002 Celli JP Turner BS Afdhal NH Keates S Ghiran I Kelly CP et al. Helicobacter pylori moves through mucus by reducing mucin viscoelasticity Proc Natl Acad Sci U S A 2009 106 14321 6 10.1073/pnas.0903438106 19706518 PMC2732822 Navarro-Garcia F Gutierrez-Jimenez J Garcia-Tovar C Castro LA Salazar-Gonzalez H Cordova V Pic, an autotransporter protein secreted by different pathogens in the Enterobacteriaceae family, is a potent mucus secretagogue Infect Immun 2010 78 4101 9 10.1128/IAI.00523-10 20696826 PMC2950354 Putsep K Axelsson LG Boman A Midtvedt T Normark S Boman HG et al. Germ-free and colonized mice generate the same products from enteric prodefensins J Biol Chem 2000 275 40478 82 10.1074/jbc.M007816200 11010975 Wilson CL Ouellette AJ Satchell DP Ayabe T López-Boado YS Stratman JL et al. Regulation of intestinal alpha-defensin activation by the metalloproteinase matrilysin in innate host defense Science 1999 286 113 7 10.1126/science.286.5437.113 10506557 Boneca IG Dussurget O Cabanes D Nahori M Sousa S Lecuit M et al. A critical role for peptidoglycan N-deacetylation in Listeria evasion from the host innate immune system Proc Natl Acad Sci U S A 2007 104 997 1002 10.1073/pnas.0609672104 17215377 PMC1766339 Iimura M Gallo RL Hase K Miyamoto Y Eckmann L Kagnoff MF Cathelicidin mediates innate intestinal defense against colonization with epithelial adherent bacterial pathogens J Immunol 2005 174 4901 7 10.4049/jimmunol.174.8.4901 15814717 Cash HL Whitham CV Behrendt CL Hooper LV Symbiotic bacteria direct expression of an intestinal bactericidal lectin Science 2006 313 1126 30 10.1126/science.1127119 16931762 PMC2716667 Bonamy C Sechet E Amiot A Alam A Mourez M Fraisse L et al. Expression of the human antimicrobial peptide β-defensin-1 is repressed by the EGFR-ERK-MYC axis in colonic epithelial cells Sci Rep 2018 8 18043 10.1038/s41598-018-36387-z 30575780 PMC6303337 Zhao X Lu M Liu Z Zhang M Yuan H Dan Z et al. Comprehensive analysis of alfa defensin expression and prognosis in human colorectal cancer Front Oncol 2023 12 974654 10.3389/fonc.2022.974654 36703795 PMC9872005 Porter RJ Murray GI Alnabulsi A Humphries MP James JA Salto-Tellez M et al. Colonic epithelial cathelicidin (LL-37) expression intensity is associated with progression of colorectal cancer and presence of CD8+ T cell infiltrate J Pathol Clin Res 2021 7 495 506 10.1002/cjp2.222 33988317 PMC8363930 Macpherson AJ Uhr T Induction of protective IgA by intestinal dendritic cells carrying commensal bacteria Science 2004 303 1662 5 10.1126/science.1091334 15016999 Rescigno M Urbano M Valzasina B Francolini M Rotta G Bonasio R et al. Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria Nat Immunol 2001 2 361 7 10.1038/86373 11276208 Suzuki K Meek B Doi Y Muramatsu M Chiba T Honjo T et al. Aberrant expansion of segmented filamentous bacteria in IgA-deficient gut Proc Natl Acad Sci U S A 2004 101 1981 6 10.1073/pnas.0307317101 14766966 PMC357038 Kau AL Planer JD Liu J Rao S Yatsunenko T Trehan I et al. Functional characterization of IgA-targeted bacterial taxa from undernourished Malawian children that produce diet-dependent enteropathy Sci Transl Med 2015 7 276ra24 10.1126/scitranslmed.aaa4877 25717097 PMC4423598 Muthuswamy RV Sundström P Börjesson L Gustavsson B Quiding-Järbrink M Impaired migration of IgA-secreting cells to colon adenocarcinomas Cancer Immunol Immunother 2013 62 989 97 10.1007/s00262-013-1410-1 23591979 PMC11028846 Nagaishi T Watabe T Kotake K Kumazawa T Aida T Tanaka K et al. Immunoglobulin A-specific deficiency induces spontaneous inflammation specifically in the ileum Gut 2022 71 487 96 10.1136/gutjnl-2020-322873 33963042 PMC8809603 Tang Y Feng X Lu Q Cui C Yu M Wen Z et al. MZB1-mediated IgA secretion suppresses the development and progression of colorectal cancer triggered by gut inflammation Mucosal Immunol 2024 17 450 60 10.1016/j.mucimm.2023.12.002 38101774 Akira S Uematsu S Takeuchi O Pathogen recognition and innate immunity Cell 2006 124 783 801 10.1016/j.cell.2006.02.015 16497588 Chamaillard M Hashimoto M Horie Y Masumoto J Qiu S Saab L et al. An essential role for NOD1 in host recognition of bacterial peptidoglycan containing diaminopimelic acid Nat Immunol 2003 4 702 7 10.1038/ni945 12796777 Kobayashi KS Chamaillard M Ogura Y Henegariu O Inohara N Nuñez G et al. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract Science 2005 307 731 4 10.1126/science.1104911 15692051 Hooper LV Midtvedt T Gordon JI How host-microbial interactions shape the nutrient environment of the mammalian intestine Annu Rev Nutr 2002 22 283 307 10.1146/annurev.nutr.22.011602.092259 12055347 Ivanov II de Llanos Frutos Rosa Manel N Yoshinaga K Rifkin DB Sartor RB et al. Specific microbiota direct the differentiation of IL-17-producing T-helper cells in the mucosa of the small intestine Cell Host Microbe 2008 4 337 49 10.1016/j.chom.2008.09.009 18854238 PMC2597589 Fukata M Shang L Santaolalla R Sotolongo J Pastorini C España C et al. Constitutive activation of epithelial TLR4 augments inflammatory responses to mucosal injury and drives colitis-associated tumorigenesis Inflamm Bowel Dis 2011 17 1464 73 10.1002/ibd.21527 21674704 PMC3117047 Fukata M Hernandez Y Conduah D Cohen J Chen A Breglio K et al. Innate immune signaling by Toll-like receptor-4 (TLR4) shapes the inflammatory microenvironment in colitis-associated tumors Inflamm Bowel Dis 2009 15 997 1006 10.1002/ibd.20880 19229991 PMC2712657 Pastille E Faßnacht T Adamczyk A Phuong NNT Buer J Westendorf AM Inhibition of TLR4 Signaling Impedes Tumor Growth in Colitis-Associated Colon Cancer Front Immunol 2021 12 669747 10.3389/fimmu.2021.669747 34025672 PMC8138317 Luo Q Zeng L Tang C Zhang Z Chen Y Zeng C TLR9 induces colitis-associated colorectal carcinogenesis by regulating NF-κB expression levels Oncol Lett 2020 20 110 10.3892/ol.2020.11971 32863923 PMC7448563 Sameer AS Nissar S Toll-Like Receptors (TLRs): Structure, Functions, Signaling, and Role of Their Polymorphisms in Colorectal Cancer Susceptibility Biomed Res Int 2021 2021 1157023 10.1155/2021/1157023 34552981 PMC8452412 Udden SMN Peng L Gan J Shelton JM Malter JS Hooper LV et al. NOD2 Suppresses Colorectal Tumorigenesis via Downregulation of the TLR Pathways Cell Rep 2017 19 2756 70 10.1016/j.celrep.2017.05.084 28658623 PMC6032983 Tralongo P Tomasello G Sinagra E Damiani P Leone A Palumbo VD et al. The role of butyric acid as a protective agent against inflammatory bowel diseases Euromediterr Biomed J 2014 9 24 35 10.3269/1970-5492.2014.9.4 Parekh PJ Balart LA Johnson DA The Influence of the Gut Microbiome on Obesity, Metabolic Syndrome and Gastrointestinal Disease Clin Transl Gastroenterol 2015 6 e91 10.1038/ctg.2015.16 26087059 PMC4816244 Lozupone CA Stombaugh JI Gordon JI Jansson JK Knight R Diversity, stability and resilience of the human gut microbiota Nature 2012 489 220 30 10.1038/nature11550 22972295 PMC3577372 Wen L Duffy A Factors Influencing the Gut Microbiota, Inflammation, and Type 2 Diabetes J Nutr 2017 147 1468S 75S 10.3945/jn.116.240754 28615382 PMC5483960 Yang J Wu J Li Y Zhang Y Cho WC Ju X et al. Gut bacteria formation and influencing factors FEMS Microbiol Ecol 2021 97 fiab043 10.1093/femsec/fiab043 33705527 Matute SP Iyavoo S Exploring the gut microbiota: lifestyle choices, disease associations, and personal genomics Front Nutr 2023 10 1225120 10.3389/fnut.2023.1225120 37867494 PMC10585655 Tomasello G Abruzzo A Sinagra E Damiani P Damiani F Traina G et al. Nutrition in IBD patient’s: what are the prospects? Prog Nutr 2015 17 79 86 Putignani L Del Chierico F Petrucca A Vernocchi P Dallapiccola B The human gut microbiota: a dynamic interplay with the host from birth to senescence settled during childhood Pediatr Res 2014 76 2 10 10.1038/pr.2014.49 24732106 Hou K Wu Z Chen X Wang J Zhang D Xiao C et al. Microbiota in health and diseases Signal Transduct Target Ther 2022 7 135 10.1038/s41392-022-00974-4 35461318 PMC9034083 Kostic AD Gevers D Pedamallu CS Michaud M Duke F Earl AM et al. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma Genome Res 2012 22 292 8 10.1101/gr.126573.111 22009990 PMC3266036 Wang N Fang J Fusobacterium nucleatum, a key pathogenic factor and microbial biomarker for colorectal cancer Trends Microbiol 2023 31 159 72 10.1016/j.tim.2022.08.010 36058786 Tomasello G Tralongo P Damiani P Sinagra E Di Trapani B Zeenny MN et al. Dismicrobism in inflammatory bowel disease and colorectal cancer: changes in response of colocytes World J Gastroenterol 2014 20 18121 30 10.3748/wjg.v20.i48.18121 25561781 PMC4277951 Sinagra E Tomasello G Raimondo D Rossi F Facella T Cappello F et al. Nutrition, malnutrition and dietary interventions in inflammatory bowel disease Prog Nutr 2014 16 79 89 de Souza HS Fiocchi C Immunopathogenesis of IBD: current state of the art Nat Rev Gastroenterol Hepatol 2016 13 13 27 10.1038/nrgastro.2015.186 26627550 Bellavia M Tomasello G Romeo M Damiani P Monte AIL Lozio L et al. Gut microbiota imbalance and chaperoning system malfunction are central to ulcerative colitis pathogenesis and can be counteracted with specifically designed probiotics: a working hypothesis Med Microbiol Immunol 2013 202 393 406 10.1007/s00430-013-0305-2 23864544 Ananthakrishnan AN Epidemiology and risk factors for IBD Nat Rev Gastroenterol Hepatol 2015 12 205 17 10.1038/nrgastro.2015.34 25732745 Venegas DP De la Fuente MK Landskron G González MJ Quera R Dijkstra G et al. Short Chain Fatty Acids (SCFAs)-Mediated Gut Epithelial and Immune Regulation and Its Relevance for Inflammatory Bowel Diseases Front Immunol 2019 10 277 10.3389/fimmu.2019.00277 30915065 PMC6421268 Weiss GA Hennet T Mechanisms and consequences of intestinal dysbiosis Cell Mol Life Sci 2017 74 2959 77 10.1007/s00018-017-2509-x 28352996 PMC11107543 Anand N Gorantla VR Chidambaram SB The Role of Gut Dysbiosis in the Pathophysiology of Neuropsychiatric Disorders Cells 2022 12 54 10.3390/cells12010054 36611848 PMC9818777 Zhao M Chu J Feng S Guo C Xue B He K et al. Immunological mechanisms of inflammatory diseases caused by gut microbiota dysbiosis: A review Biomed Pharmacother 2023 164 114985 10.1016/j.biopha.2023.114985 37311282 Wilmes P Martin-Gallausiaux C Ostaszewski M Aho VTE Novikova PV Laczny CC et al. The gut microbiome molecular complex in human health and disease Cell Host Microbe 2022 30 1201 6 10.1016/j.chom.2022.08.016 36108612 Olovo CV Huang X Zheng X Xu M Faecal microbial biomarkers in early diagnosis of colorectal cancer J Cell Mol Med 2021 25 10783 97 10.1111/jcmm.17010 34750964 PMC8642680 Zhang W An Y Qin X Wu X Wang X Hou H et al. Gut Microbiota-Derived Metabolites in Colorectal Cancer: The Bad and the Challenges Front Oncol 2021 11 739648 10.3389/fonc.2021.739648 34733783 PMC8558397 Silva M Brunner V Tschurtschenthaler M Microbiota and Colorectal Cancer: From Gut to Bedside Front Pharmacol 2021 12 760280 10.3389/fphar.2021.760280 34658896 PMC8514721 Pandey H Tang DWT Wong SH Lal D Gut Microbiota in Colorectal Cancer: Biological Role and Therapeutic Opportunities Cancers (Basel) 2023 15 866 10.3390/cancers15030866 36765824 PMC9913759 Tilg H Adolph TE Gerner RR Moschen AR The Intestinal Microbiota in Colorectal Cancer Cancer Cell 2018 33 954 64 10.1016/j.ccell.2018.03.004 29657127 Liu K Yang X Zeng M Yuan Y Sun J He P et al. The Role of Fecal Fusobacterium nucleatum and pks+ Escherichia coli as Early Diagnostic Markers of Colorectal Cancer Dis Markers 2021 2021 1171239 10.1155/2021/1171239 34853619 PMC8629656 Zepeda-Rivera M Minot SS Bouzek H Wu H Blanco-Míguez A Manghi P et al. A distinct Fusobacterium nucleatum clade dominates the colorectal cancer niche Nature 2024 628 424 32 10.1038/s41586-024-07182-w 38509359 PMC11006615 Jin M Shang F Wu J Fan Q Chen C Fan J et al. Tumor-Associated Microbiota in Proximal and Distal Colorectal Cancer and Their Relationships With Clinical Outcomes Front Microbiol 2021 12 727937 10.3389/fmicb.2021.727937 34650531 PMC8506159 Nouri R Hasani A Shirazi KM Alivand MR Sepehri B Sotoudeh S et al. Mucosa-Associated Escherichia coli in Colorectal Cancer Patients and Control Subjects: Variations in the Prevalence and Attributing Features Can J Infect Dis Med Microbiol 2021 2021 2131787 10.1155/2021/2131787 34795808 PMC8594973 Becker HEF Jamin C Bervoets L Boleij A Xu P Pierik MJ et al. Higher Prevalence of Bacteroides fragilis in Crohn’s Disease Exacerbations and Strain-Dependent Increase of Epithelial Resistance Front Microbiol 2021 12 598232 10.3389/fmicb.2021.598232 34168621 PMC8219053 Oehmcke-Hecht S Mandl V Naatz LT Dühring L Köhler J Kreikemeyer B et al. Streptococcus gallolyticus abrogates anti-carcinogenic properties of tannic acid on low-passage colorectal carcinomas Sci Rep 2020 10 4714 10.1038/s41598-020-61458-5 32170212 PMC7070001 Haghi F Goli E Mirzaei B Zeighami H The association between fecal enterotoxigenic B. fragilis with colorectal cancer BMC Cancer 2019 19 879 10.1186/s12885-019-6115-1 31488085 PMC6727388 Appunni S Rubens M Ramamoorthy V Tonse R Saxena A McGranaghan P et al. Emerging Evidence on the Effects of Dietary Factors on the Gut Microbiome in Colorectal Cancer Front Nutr 2021 8 718389 10.3389/fnut.2021.718389 34708063 PMC8542705 Chen F Dai X Zhou C Li K Zhang Y Lou X et al. Integrated analysis of the faecal metagenome and serum metabolome reveals the role of gut microbiome-associated metabolites in the detection of colorectal cancer and adenoma Gut 2022 71 1315 25 10.1136/gutjnl-2020-323476 34462336 PMC9185821 Kong C Liang L Liu G Du L Yang Y Liu J et al. Integrated metagenomic and metabolomic analysis reveals distinct gut-microbiome-derived phenotypes in early-onset colorectal cancer Gut 2023 72 1129 42 10.1136/gutjnl-2022-327156 35953094 Guo X Wang R Chen R Zhang Z Wang J Liu X Gut microbiota and serum metabolite signatures along the colorectal adenoma-carcinoma sequence: Implications for early detection and intervention Clin Chim Acta 2024 560 119732 10.1016/j.cca.2024.119732 38772522 Guzior DV Quinn RA Review: microbial transformations of human bile acids Microbiome 2021 9 140 10.1186/s40168-021-01101-1 34127070 PMC8204491 Larabi AB Masson HLP Bäumler AJ Bile acids as modulators of gut microbiota composition and function Gut Microbes 2023 15 2172671 10.1080/19490976.2023.2172671 36740850 PMC9904317 Cong J Liu P Han Z Ying W Li C Yang Y et al. Bile acids modified by the intestinal microbiota promote colorectal cancer growth by suppressing CD8+ T cell effector functions Immunity 2024 57 876 89.e11 10.1016/j.immuni.2024.02.014 38479384 Cao H Xu M Dong W Deng B Wang S Zhang Y et al. Secondary bile acid-induced dysbiosis promotes intestinal carcinogenesis Int J Cancer 2017 140 2545 56 10.1002/ijc.30643 28187526 Litvak Y Byndloss MX Bäumler AJ Colonocyte metabolism shapes the gut microbiota Science 2018 362 eaat9076 10.1126/science.aat9076 30498100 PMC6296223 Ohara T Mori T Antiproliferative Effects of Short-chain Fatty Acids on Human Colorectal Cancer Cells via Gene Expression Inhibition Anticancer Res 2019 39 4659 66 10.21873/anticanres.13647 31519564 Mowat C Dhatt J Bhatti I Hamie A Baker K Short chain fatty acids prime colorectal cancer cells to activate antitumor immunity Front Immunol 2023 14 1190810 10.3389/fimmu.2023.1190810 37304266 PMC10248408 Zhang Q Zhao Q Li T Lu L Wang F Zhang H et al. Lactobacillus plantarum-derived indole-3-lactic acid ameliorates colorectal tumorigenesis via epigenetic regulation of CD8+ T cell immunity Cell Metab 2023 35 943 60.e9 10.1016/j.cmet.2023.04.015 37192617 Zheng D Dong X Pan P Chen K Fan J Cheng S et al. Phage-guided modulation of the gut microbiota of mouse models of colorectal cancer augments their responses to chemotherapy Nat Biomed Eng 2019 3 717 28 10.1038/s41551-019-0423-2 31332342 Teng H Wang Y Sui X Fan J Li S Lei X et al. Gut microbiota-mediated nucleotide synthesis attenuates the response to neoadjuvant chemoradiotherapy in rectal cancer Cancer Cell 2023 41 124 38.e6 10.1016/j.ccell.2022.11.013 36563680 Xiao H Cui M Li Y Dong J Zhang S Zhu C et al. Gut microbiota-derived indole 3-propionic acid protects against radiation toxicity via retaining acyl-CoA-binding protein Microbiome 2020 8 69 10.1186/s40168-020-00845-6 32434586 PMC7241002 Tian T Zhao Y Yang Y Wang T Jin S Guo J et al. The protective role of short-chain fatty acids acting as signal molecules in chemotherapy- or radiation-induced intestinal inflammation Am J Cancer Res 2020 10 3508 31 33294252 PMC7716145 Wang Z Wang Q Wang X Zhu L Chen J Zhang B et al. Gut microbial dysbiosis is associated with development and progression of radiation enteritis during pelvic radiotherapy J Cell Mol Med 2019 23 3747 56 10.1111/jcmm.14289 30908851 PMC6484301 Routy B Le Chatelier E Derosa L Duong CPM Alou MT Daillère R et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors Science 2018 359 91 7 10.1126/science.aan3706 29097494 Jiang S Xie Y Xiao X Kang Z Lin X Zhang L et al. Fusobacterium nucleatum-derived succinic acid induces tumor resistance to immunotherapy in colorectal cancer Cell Host Microbe 2023 31 781 97.e9 10.1016/j.chom.2023.04.010 37130518 Zhang S Mao Y Zhang Z Li Z Kong C Chen H et al. Pectin supplement significantly enhanced the anti-PD-1 efficacy in tumor-bearing mice humanized with gut microbiota from patients with colorectal cancer Theranostics 2021 11 4155 70 10.7150/thno.54476 33754054 PMC7977465 Fong W Li Q Ji F Liang W Lau HCH Kang X et al. Lactobacillus gallinarum-derived metabolites boost anti-PD1 efficacy in colorectal cancer by inhibiting regulatory T cells through modulating IDO1/Kyn/AHR axis Gut 2023 72 2272 85 10.1136/gutjnl-2023-329543 37770127 PMC10715476 Chen Z Guan D Wang Z Li X Dong S Huang J et al. Microbiota in cancer: molecular mechanisms and therapeutic interventions MedComm (2020) 2023 4 e417 10.1002/mco2.417 37937304 PMC10626288 Yu T Guo F Yu Y Sun T Ma D Han J et al. Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy Cell 2017 170 548 63.e16 10.1016/j.cell.2017.07.008 28753429 PMC5767127 Zhao L Mei J Yu G Lei L Zhang W Liu K et al. Role of the gut microbiota in anticancer therapy: from molecular mechanisms to clinical applications Signal Transduct Target Ther 2023 8 201 10.1038/s41392-023-01406-7 37179402 PMC10183032 Duan B Zhao Y Bai J Wang J Duan X Luo X et al. Colorectal Cancer: An Overview Morgado-Diaz JA Gastrointestinal Cancers Brisbane (AU) Exon Publications 2022 pp. 1–12. Jafari MD Carmichael JC Dayyani F McKinney C Wenzel L Zell JA et al. Immediate Adjuvant Chemotherapy in Non-Metastatic Colon Cancer: Phase I Trial Evaluating a Novel Treatment Protocol Clin Colorectal Cancer 2022 21 114 21 10.1016/j.clcc.2021.11.004 34980534 PMC9844669 Wang J Li S Liu Y Zhang C Li H Lai B Metastatic patterns and survival outcomes in patients with stage IV colon cancer: A population-based analysis Cancer Med 2020 9 361 73 10.1002/cam4.2673 31693304 PMC6943094 Chen Y Wang X Ye Y Ren Q Gut microbiota in cancer: insights on microbial metabolites and therapeutic strategies Med Oncol 2023 41 25 10.1007/s12032-023-02249-6 38129370 Chen Y Liao X Li Y Cao H Zhang F Fei B et al. Effects of prebiotic supplement on gut microbiota, drug bioavailability, and adverse effects in patients with colorectal cancer at different primary tumor locations receiving chemotherapy: study protocol for a randomized clinical trial Trials 2023 24 268 10.1186/s13063-023-07137-y 37046334 PMC10091326 Franko J Raman S Patel S Petree B Lin M Tee MC et al. Survival and cancer recurrence after short-course perioperative probiotics in a randomized trial Clin Nutr ESPEN 2024 60 59 64 10.1016/j.clnesp.2024.01.003 38479940 Xu F Li Q Wang S Dong M Xiao G Bai J et al. The efficacy of prevention for colon cancer based on the microbiota therapy and the antitumor mechanisms with intervention of dietary Lactobacillus Microbiol Spectr 2023 11 e0018923 10.1128/spectrum.00189-23 37655887 PMC10581183 Mego M Chovanec J Vochyanova-Andrezalova I Konkolovsky P Mikulova M Reckova M et al. Prevention of irinotecan induced diarrhea by probiotics: A randomized double blind, placebo controlled pilot study Complement Ther Med 2015 23 356 62 10.1016/j.ctim.2015.03.008 26051570 Polakowski CB Kato M Preti VB Schieferdecker MEM Campos ACL Impact of the preoperative use of synbiotics in colorectal cancer patients: A prospective, randomized, double-blind, placebo-controlled study Nutrition 2019 58 40 6 10.1016/j.nut.2018.06.004 30278428 Kvakova M Kamlarova A Stofilova J Benetinova V Bertkova I Probiotics and postbiotics in colorectal cancer: Prevention and complementary therapy World J Gastroenterol 2022 28 3370 82 10.3748/wjg.v28.i27.3370 36158273 PMC9346452 Shao S Jia R Zhao L Zhang Y Guan Y Wen H et al. Xiao-Chai-Hu-Tang ameliorates tumor growth in cancer comorbid depressive symptoms via modulating gut microbiota-mediated TLR4/MyD88/NF-κB signaling pathway Phytomedicine 2021 88 153606 10.1016/j.phymed.2021.153606 34111616 Yu H Li X Han X Chen B Zhang X Gao S et al. Fecal microbiota transplantation inhibits colorectal cancer progression: Reversing intestinal microbial dysbiosis to enhance anti-cancer immune responses Front Microbiol 2023 14 1126808 10.3389/fmicb.2023.1126808 37143538 PMC10151806 Van Dingenen L Segers C Wouters S Mysara M Leys N Kumar-Singh S et al. Dissecting the role of the gut microbiome and fecal microbiota transplantation in radio- and immunotherapy treatment of colorectal cancer Front Cell Infect Microbiol 2023 13 1298264 10.3389/fcimb.2023.1298264 38035338 PMC10687483 Song M Chan AT Sun J Influence of the Gut Microbiome, Diet, and Environment on Risk of Colorectal Cancer Gastroenterology 2020 158 322 40 10.1053/j.gastro.2019.06.048 31586566 PMC6957737 Rebersek M Gut microbiome and its role in colorectal cancer BMC Cancer 2021 21 1325 10.1186/s12885-021-09054-2 34895176 PMC8666072 Yang J Wei H Zhou Y Szeto C Li C Lin Y et al. High-Fat Diet Promotes Colorectal Tumorigenesis Through Modulating Gut Microbiota and Metabolites Gastroenterology 2022 162 135 49.e2 10.1053/j.gastro.2021.08.041 34461052 Molan A Liu Z Plimmer G Evaluation of the effect of blackcurrant products on gut microbiota and on markers of risk for colon cancer in humans Phytother Res 2014 28 416 22 10.1002/ptr.5009 23674271 Song M Garrett WS Chan AT Nutrients, foods, and colorectal cancer prevention Gastroenterology 2015 148 1244 60.e16 10.1053/j.gastro.2014.12.035 25575572 PMC4409470 Aune D Lau R Chan DSM Vieira R Greenwood DC Kampman E et al. Dairy products and colorectal cancer risk: a systematic review and meta-analysis of cohort studies Ann Oncol 2012 23 37 45 10.1093/annonc/mdr269 21617020 Kumar A Chinnathambi S Kumar M Pandian GN Food Intake and Colorectal Cancer Nutr Cancer 2023 75 1710 42 10.1080/01635581.2023.2242103 37572059 Bullman S Pedamallu CS Sicinska E Clancy TE Zhang X Cai D et al. Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer Science 2017 358 1443 8 10.1126/science.aal5240 29170280 PMC5823247 Wang M Rousseau B Qiu K Huang G Zhang Y Su H et al. Killing tumor-associated bacteria with a liposomal antibiotic generates neoantigens that induce anti-tumor immune responses Nat Biotechnol 2024 42 1263 74 10.1038/s41587-023-01957-8 37749267